Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
41
AMGN Quote, Financials, Valuation and Earnings
Last price:
$330.08
Seasonality move
:
5.99%
Day range:
$318.21 - $326.52
52-week range:
$257.05 - $346.38
Dividend yield:
2.97%
P/E ratio:
24.79x
P/S ratio:
4.84x
P/B ratio:
17.95x
Volume:
2.3M
Avg. volume:
2.8M
1-year change:
22.78%
Market cap:
$172.7B
Revenue:
$33.2B
EPS (TTM):
$12.94
Analysts' Opinion
-
Consensus RatingAmgen, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 10 Buy ratings, 15 Hold ratings, and 2 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $327.74, Amgen, Inc. has an estimated upside of 2.19% from its current price of $320.72.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $180.00 representing 100% downside risk from its current price of $320.72.
Fair Value
-
According to the consensus of 27 analysts, Amgen, Inc. has 2.19% upside to fair value with a price target of $327.74 per share.
AMGN vs. S&P 500
-
Over the past 5 trading days, Amgen, Inc. has underperformed the S&P 500 by -4.46% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Amgen, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Amgen, Inc. has grown year-over-year revenues for 10 quarters straight. In the most recent quarter Amgen, Inc. reported revenues of $9.6B.
Earnings Growth
-
Amgen, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Amgen, Inc. reported earnings per share of $5.93.
Enterprise value:
217.8B
EV / Invested capital:
--
Price / LTM sales:
4.84x
EV / EBIT:
21.25x
EV / Revenue:
6.07x
PEG ratio (5yr expected):
0.38x
EV / Free cash flow:
18.88x
Price / Operating cash flow:
15.05x
Enterprise value / EBITDA:
13.89x
Gross Profit (TTM):
$25.3B
Return On Assets:
7.78%
Net Income Margin (TTM):
19.52%
Return On Equity:
95.55%
Return On Invested Capital:
10.74%
Operating Margin:
26.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $26.6B | $32.3B | $35.9B | $8.5B | $9.6B | |
| Gross Profit | $19.5B | $19.5B | $25.3B | $5.1B | $6.5B | |
| Operating Income | $8.7B | $6.5B | $10.3B | $2B | $2.6B | |
| EBITDA | $12.3B | $12.1B | $15.7B | $3.4B | $3.9B | |
| Diluted EPS | $14.06 | $7.81 | $12.94 | $5.22 | $5.93 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $24.4B | $24.1B | $48.5B | $26.8B | $27.9B | |
| Total Assets | $65B | $63.7B | $90.5B | $90.9B | $90.1B | |
| Current Liabilities | $14.8B | $14.3B | $17B | $20.3B | $21.8B | |
| Total Liabilities | $56.8B | $60B | $82.9B | $83.4B | $80.5B | |
| Total Equity | $8.2B | $3.7B | $7.7B | $7.5B | $9.6B | |
| Total Debt | $37.6B | $38.7B | $60.5B | $60.4B | $54.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $10.6B | $7.3B | $13.1B | $3.6B | $4.7B | |
| Cash From Investing | -$2.6B | -$27.7B | -$1.7B | -$210M | -$414M | |
| Cash From Financing | $17.2B | -$5.3B | -$11B | -$3.7B | -$2.9B | |
| Free Cash Flow | $9.4B | $6.3B | $11.5B | $3.3B | $4.2B | |
AMGN
Sector
Market Cap
$172.7B
$28.1M
Price % of 52-Week High
92.59%
50.9%
Dividend Yield
2.97%
0%
Shareholder Yield
4.52%
-1.55%
1-Year Price Total Return
22.78%
-19.36%
Beta (5-Year)
0.454
0.498
Dividend yield:
2.97%
Annualized payout:
$9.00
Payout ratio:
40.11%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$329.05
200-day SMA
Buy
Level
$297.79
Bollinger Bands (100)
Buy
Level
283.73 - 328.41
Chaikin Money Flow
Buy
Level
2.1B
20-day SMA
Sell
Level
$325.45
Relative Strength Index (RSI14)
Sell
Level
42.19
ADX Line
Sell
Level
16.06
Williams %R
Buy
Level
-84.4774
50-day SMA
Sell
Level
$324.15
MACD (12, 26)
Buy
Level
0.30
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
28.1B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.2944)
Sell
CA Score
(Annual)
Level (-1.9324)
Buy
Beneish M-Score
(Annual)
Level (-2.8796)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (1.4349)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Stock Forecast FAQ
In the current month, AMGN has received 10 Buy ratings 15 Hold ratings, and 2 Sell ratings. The AMGN average analyst price target in the past 3 months is $327.74.
-
Where Will Amgen, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Amgen, Inc. share price will rise to $327.74 per share over the next 12 months.
-
What Do Analysts Say About Amgen, Inc.?
Analysts are divided on their view about Amgen, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Amgen, Inc. is a Sell and believe this share price will drop from its current level to $180.00.
-
What Is Amgen, Inc.'s Price Target?
The price target for Amgen, Inc. over the next 1-year time period is forecast to be $327.74 according to 27 Wall Street analysts, 10 of them rate the stock a Buy, 2 rate the stock a Sell, and 15 analysts rate the stock a Hold.
-
Is AMGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Amgen, Inc. is a Hold. 15 of 27 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of AMGN?
You can purchase shares of Amgen, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Amgen, Inc. shares.
-
What Is The Amgen, Inc. Share Price Today?
Amgen, Inc. was last trading at $330.08 per share. This represents the most recent stock quote for Amgen, Inc.. Yesterday, Amgen, Inc. closed at $320.72 per share.
-
How To Buy Amgen, Inc. Stock Online?
In order to purchase Amgen, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get AMGN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AMGN
Sector
P/E ratio
24.79x
24.09x
PEG ratio
0.38x
-0.01x
P/B ratio
17.95x
1.83x
Price / LTM sales
4.84x
1.59x
Growth Metrics
AMGN
Sector
Revenue growth
13.33%
4.68%
Earnings growth
13.64%
10.88%
Revenue (5-year growth)
7.4%
6.45%
Earnings forecast
$4.74
-$0.18
Profitability
AMGN
Sector
Profitability FY 2024
$21.3B
$3.6M
Return on invested capital
10.74%
-31.87%
Return on assets
7.78%
-28.18%
Return on equity
95.55%
-37.89%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
3
Estimated Next Earnings Date
Feb
3
Balance Sheet
AMGN
Sector
Total cash
$9.4B
$26.2M
Short term investments
--
$25.7M
Total assets
$91.8B
$76.7M
Long term debt
$54.6B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
